Samsung Biologics, a leading contract development and manufacturing organization (CDMO), has been honored with multiple accolades at the 2026 CDMO Leadership Awards, presented by Outsourced Pharma and Life Science Connect.

The company claimed the Sustainability Leadership Award, recognizing its efforts to advance sustainable practices across operations and the broader value chain. It also earned the title “Best in Class” for Cultural Fit in the ‘Biologics—Large CDMOs’ category, highlighting its collaborative partnerships and alignment with client needs.

The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers, drawing on global client feedback in areas such as facilities, innovation, technical expertise, and manufacturing capabilities.

This year’s Jury Awards were determined by an independent panel of industry experts, informed by survey data and broader industry input. Samsung Biologics has consistently earned recognition, with clients praising its reliable execution and consistent service quality.

Attending the ceremony in New York during DCAT Week, Samsung Biologics framed the honors as a reflection of its ongoing commitment to stable, resilient, and sustainable practices that support client programs.

"Sustainability is a core value at Samsung Biologics and guides how we pursue excellence throughout our business and partnerships," said John Rim, President and CEO of Samsung Biologics, who also serves as champion for the Sustainable Markets Initiative (SMI) Supply Chains Working Group.

"This recognition reflects the trust our clients and partners continue to place in us, as well as the dedication of our teams who consistently strive to integrate sustainable practices across our operations. We will continue to advance these efforts in close collaboration with our partners, supporting their long-term goals and the delivery of high-quality, life-saving medicines to patients worldwide."